|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228显示文摘 | Sandor V Senderowicz A Mertins S | 2000 | Br J Cancer2000，83，6： | 1 |
| 2 | Phase Ⅰ trial of contimuous infusion flavopiridol,a novel cyclin-dependent kinase inhibitor,in patients with refractory neoplasms显示文摘 | Senderowicz A M Headlee D Stinson S F | 1998 | J Clin Oncol1998，16，9： | 1 |
| 3 | P21-depen- dent G~ arrest with downregnlation of cyclin D1 and upre- gulation of cyclin E by the histone deacetylase inhibitor FR901228显示文摘 | Sandor V Senderowicz A Mertins S | 2000 | Br J Cancer2000，83，6： | 1 |
| 4 | Preclinical and clinical development of cyclin-dependent kinase modulators 显示文摘 | SENDEROWICZ A M SAUSVILLE E A | 2000 | Natl Cancer Inst2000，92，5： | 1 |
| 5 | Novel direct and indirect cyclin -dependent kinase modulators for the prevention and treatment of human neoplasms显示文摘 | Senderowicz A M | 2003 | Cancer Chemother Pharmacol2003，52，： | 1 |
| 6 | Flavopiridol: the First Cyclin - Dependent Kinase Inhibitor in Human Clinical Trials 显示文摘 | Senderowicz A | 1999 | Invest New Drugs1999，17，3： | 1 |
| 7 | Possible mechanism of diarrhe',d side effects associated with the use of a novel chemo-therapeutic agent, flavopiridol显示文摘 | Kahn ME Senderowicz A SausviUe EA | 2001 | Clin Cancer Res2001，7，： | 1 |
| 8 | Fla- vopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development显示文摘 | ZHAI S SENDEROWICZ A M SAUSVILLE E A | 2002 | Ann Pharmacol2002，36，： | 1 |
| 9 | Small-molecule cyclin-dependent kinase modulators显示文摘 | Senderowicz A M | 2003 | Oncogene2003，22，： | 1 |
| 10 | P21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228显示文摘 | SANDOR V SENDEROWICZ A MERTINS S | 2000 | BrJ Cancer2000，83，6： | 1 |
| 11 | Phase Ⅰ trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms 显示文摘 | SENDEROWICZ A M HEADLEE D STINSON S F | 1998 | J Clin Oncol1998，16，9： | 1 |
| 12 | The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01显示文摘 | Senderowicz A M | 2002 | Oncologist2002，7，3： | 1 |
| 13 | Possible Mechanisms of Diarrheal Side Effects Associated with the Use of a Novel Chemotherapeutic Agent, Flavopiridol 显示文摘 | KAHN M E S SENDEROWICZ A SAUSVILLE E A | 2001 | Clin Cancer Res2001，7，2： | 1 |
| 14 | Possible mechanisms of diarrhea side effects associated with the use of a novel chemotherapeutic agent,flavopiridos显示文摘 | Kahn ME Senderowicz A Sausville EA | 2001 | Clinical Cancer Research2001，7，2： | 1 |
| 15 | Activated protein C resistance(factor V Leiden)associated with thrombosis in pregnancy显示文摘 | Hallak M Senderowicz J Cassel A | 1997 | Am J Obstet Gynecol1997，176，： | 1 |
| 16 | RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells 显示文摘 | MUKHOPADHYAY U K SENDEROWICZ A M FERBEYRE G | 2005 | Cancer Res2005，65，： | 1 |
| 17 | Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent,flavopiridol显示文摘 | Kahn ME Senderowicz A Sausville EA | 2001 | Clin Cancer Res2001，7，2： | 1 |
| 18 | Erlotinib/gemcitabine for first - line treatment of locally advanced or metastatic adenocarcinoma of the pancreas显示文摘 | SENDEROWICZ A M JOHNSON J R SRIDHARA R | 2007 | Oncology (Williston Park)2007，21，14： | 1 |
| 19 | Lymphotoxins and Cytomegalovirus Cooperatively Induce Interferon-β, Establishing Host-Virus Détente显示文摘 | Chris A Benedict Theresa A Banks Lionel Senderowicz Mira Ko William J Britt Ana Angulo Peter Ghazal Carl F Ware | 2001 | Immunity2001，，： | 1 |
| 20 | Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms显示文摘 | Senderowicz A M | 2003 | Cancer Chemother Pharmacol2003，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员